Ticker

No recent analyst price targets found for HBPCF.

Latest News for HBPCF

Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development

Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations . The…

TheNewswire • Jun 30, 2026
Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026

Vancouver, British Columbia – TheNewswire - June 12, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today reported financial results and the filing of the Company's unaudited interim financial statements as of and for the three- and nine-month…

TheNewswire • Jun 12, 2026
Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures

Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “ Offering ”) of unsecured convertible debentures of the Company (each, a “…

TheNewswire • Jun 3, 2026
Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options

Toronto, Ontario – TheNewswire - May 22, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced that the board of directors has granted 1,297,000 incentive stock options to directors, officers, employees and consultants of the Company…

TheNewswire • May 22, 2026
Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy

Toronto, Ontario – TheNewswire - 13 May, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce the following appointments, effective immediately: Zachary T. Stadnyk, former TSX Life Sciences Lead and a biotech capital markets…

TheNewswire • May 13, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for HBPCF.

No Senate trades found for HBPCF.

No House trades found for HBPCF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top